Chemical formula: C₂₈H₃₀N₂O₂ Molecular mass: 426.55 g/mol PubChem compound: 444031
Darifenacin is a selective muscarinic M3 receptor antagonist (M3 SRA) in vitro. The M3 receptor is the major subtype that controls urinary bladder muscle contraction. It is not known whether this selectivity for the M3 receptor translates into any clinical advantage when treating symptoms of overactive bladder syndrome.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| G04BD10 | Darifenacin | G Genito urinary system and sex hormones → G04 Urologicals → G04B Other urologicals, incl. antispasmodics → G04BD Urinary antispasmodics |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| ENABLEX Extended-release tablet | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| EMSELEX Prolonged-release tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
Darifenacin is an active ingredient of these brands:
United States (US)
Austria (AT)
Canada (CA)
Croatia (HR)
Cyprus (CY)
Estonia (EE)
Finland (FI)
Germany (DE)
Hong Kong (HK)
Ireland (IE)
Lithuania (LT)
Mexico (MX)
Netherlands (NL)
New Zealand (NZ)
Poland (PL)
Romania (RO)
South Africa (ZA)Turkey (TR)
United Kingdom (UK)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
